15:30 | OCTA-5 years’ experience. Benefits and limitations

Adnan Tufail

15:40 | Multi-modal imaging in assessing maculopathy – What is best for what

Adnan Tufail

15:50 | The future-art. Intelligence

Adnan Tufail

16:00 | OCT biomarkers in DME: What responds to which intravitreal injection

Francesco Pichi

16:10 | OCTA in vascular abnormalities and ischemic changes in DRchi

Ibraheem Elghrably

16:20 | Q&A / Discussion